MX2018009921A - Pharmaceutical composition for preventing and treating sleep disorders. - Google Patents

Pharmaceutical composition for preventing and treating sleep disorders.

Info

Publication number
MX2018009921A
MX2018009921A MX2018009921A MX2018009921A MX2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A
Authority
MX
Mexico
Prior art keywords
sleep disorders
preventing
pharmaceutical composition
treating sleep
composition
Prior art date
Application number
MX2018009921A
Other languages
Spanish (es)
Inventor
Viktorovich Nesteruk Vladimir
Konstantinovich Syrov Kirill
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of MX2018009921A publication Critical patent/MX2018009921A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the field of medicine and to the chemical-pharmaceutical industry, and pertains to agents for use in the case of sleep disorders. A pharmaceutical composition for initiating and maintaining the sleep process and for preventing, in animals and humans, conditions associated with various types of sleep disorders, said composition being characterized in that it includes effective quantities of doxylamine succinate and slow-release melatonin. The technical result consists in synergistic therapeutic effects, biological succession, and reduced side effects.
MX2018009921A 2016-02-18 2017-02-16 Pharmaceutical composition for preventing and treating sleep disorders. MX2018009921A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016105535A RU2620855C1 (en) 2016-02-18 2016-02-18 Pharmaceutical composition for sleep disorders prevention and treatment
PCT/RU2017/000077 WO2017142442A1 (en) 2016-02-18 2017-02-16 Pharmaceutical composition for preventing and treating sleep disorders

Publications (1)

Publication Number Publication Date
MX2018009921A true MX2018009921A (en) 2018-11-09

Family

ID=59032329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009921A MX2018009921A (en) 2016-02-18 2017-02-16 Pharmaceutical composition for preventing and treating sleep disorders.

Country Status (9)

Country Link
KR (1) KR20180101539A (en)
CN (1) CN108697645A (en)
BR (1) BR112018016725A2 (en)
CL (1) CL2018002337A1 (en)
EA (1) EA201891647A1 (en)
HK (1) HK1255631A1 (en)
MX (1) MX2018009921A (en)
RU (1) RU2620855C1 (en)
WO (1) WO2017142442A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517040A (en) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド Melatonin combination therapy to improve sleep quality
US9700548B2 (en) * 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
FR3000896B1 (en) * 2013-01-14 2016-08-26 Philippe Perovitch GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS
DK2964185T3 (en) * 2013-03-05 2022-02-14 Requis Pharmaceuticals Inc PREPARATIONS FOR THE TREATMENT OF SLEEP-RELATED RESPIRATORY DISORDERS

Also Published As

Publication number Publication date
CL2018002337A1 (en) 2018-11-30
KR20180101539A (en) 2018-09-12
HK1255631A1 (en) 2019-08-23
RU2620855C1 (en) 2017-05-30
EA201891647A1 (en) 2018-12-28
BR112018016725A2 (en) 2019-04-30
WO2017142442A1 (en) 2017-08-24
CN108697645A (en) 2018-10-23

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020009780A (en) Autotaxin inhibitor compounds.
BR112017003546A2 (en) heterocyclic amides as rip1 kinase inhibitors as drugs
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017009798A2 (en) polymeric hgh prodrugs
NZ751746A (en) Combination therapy with controlled-release cnp agonists
MX2017002364A (en) Combination therapy for treatment of cancer.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201991175A1 (en) THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS
HK1257583A1 (en) Medicine for preventing and treating fat metabolism disorders and related diseases and use of the medicine
MX2017011018A (en) Inhibition of olig2 activity.
ZA201901367B (en) Inhibition of olig2 activity
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
MX2018009921A (en) Pharmaceutical composition for preventing and treating sleep disorders.
AR103636A1 (en) METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND
PH12020500472A1 (en) Autotaxin inhibitor compounds
RU2014107146A (en) METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS
MX2023005681A (en) Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol.
IL271592A (en) Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases
TH170136B (en) The new indasol carboxamide The process of preparing such substances; pharmaceutical preparations which contain such substances And the use of such substances In drug production
TH181273A (en) Pharmaceutical components containing AMPK activators and serotonergic agents. And how to use this